In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

Substantial improvements in diagnostics and treatments have been obtained for patients with cystic fibrosis (CF), resulting in a tremendously improved prognosis for the patients [1]. However, chronic lung infections remain the major cause for premature death in CF patients [1], especially with Pseudomonas aeruginosa. It is generally accepted that biofilm formation in the lungs of patients with CF or chronic lung disease (e.g. bronchiectasis) provides the mechanism leading to the persistent airway infections, since biofilm growth renders the bacteria tolerant to the host response and to antibiotics [2].

Source: Journal of Cystic Fibrosis - February 13, 2020 Category: Respiratory Medicine Authors: Lars Christophersen, Franziska Angelika Schwartz, Christian Johann Lerche, Trine Svanekj ær, Kasper Nørskov Kragh, Anne Sofie Laulund, Kim Thomsen, Kaj-Åge Henneberg, Thomas Sams, Niels Høiby, Claus Moser Tags: Original Article Source Type: research